Clinical trial
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Dotinurad in Adult Participants With Gout Who Are Intolerant to Xanthine Oxidase Inhibitors or Failed Uricase Treatment
NCT07535034 is registered in ClinicalTrials.gov with Crystalys Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Dotinurad in Adult Participants With Gout Who Are Intolerant to Xanthine Oxidase Inhibitors or Failed Uricase Treatment
- Lead sponsor
- Crystalys Therapeutics
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- May 8, 2026
- Completion date
- August 31, 2027
- Enrollment
- 90 (estimated)
- Sites
- 41
Conditions
As the registry lists them; a condition with its own page is linked.